The 2018-19 Leadership Development Program has 16 participants from various practice settings, subspecialties, and geographic locations.

Participant Biographies

Tareq Al baghdadi, MDTareq Al baghdadi, MD
St. Joseph Mercy Hospital in Ann Arbor

Tareq Al baghdadi, MD, is a community-based oncologist. After completing a fellowship in Hematology/Oncology at Indiana University in 2011, Dr. Al baghdadi joined IHA hematology oncology consultants in Ann Arbor.

Dr. Al baghdadi is the Co-PI for the Michigan Cancer Research Consortium (NCORP) and has served as the local PI for multiple NCTN- and pharma-sponsored trials. He also serves on the tumor molecular board at St. Joseph Mercy Hospital in Ann Arbor. Dr. Al baghdadi serves on multiple national committees including the NCI leukemia steering committee, the ABIM oncology board, the Alliance community oncology leadership committee and the national MDS trial leadership committee. His academic interests include clinical research and urologic and hematologic malignancies.


Carey K. Anders, MDCarey K. Anders, MD
UNC Chapel Hill/Lineberger Comprehensive Cancer Center

Carey K. Anders, MD, is an Associate Professor of Medicine at the University of North Carolina (UNC) School of Medicine and an active member of the UNC Lineberger Comprehensive Cancer Center (LCCC) and co-leader of the LCCC Breast Program. As a clinician-scientist, she is Section Leader for the UNC Breast Program, Leader of the UNC breast cancer clinical trials program, and co-Director of the multi-disciplinary brain metastases clinic at UNC. 

Dr. Anders’ translational research program, which spans bench to bedside, focuses on the biology of triple negative breast cancer and brain metastases.

She serves as the principal investigator for multiple clinical trials evaluating novel anti-cancer agents to more effectively treat patients with advanced triple negative breast cancer and brain metastases. In parallel, and supported by the UNC Chapel Hill Hematology Oncology K12, NIH/NCI K23, LCCC SPORE and Damon Runyon Clinical Investigator Award, she has developed multiple intracranial breast cancer tumor models to test novel therapies, including small molecule and nanoparticle chemotherapeutics in the laboratory. She is also devoted to uncovering the genetic and genomic underpinnings of triple negative breast cancer and brain metastases using Next Generation Sequencing, the focus of her American Society of Clinical Oncology Advanced Clinical Research Award.  Her ultimate goal is to translate preclinical findings into rationally-designed therapeutic strategies to improve survival and enhance quality of life for the many patients facing a diagnosis of triple negative breast cancer brain metastases. 


Aditya Bardia, MDAditya Bardia, MD
Massachusetts General Hospital, Harvard Medical School

Aditya Bardia, MD, is a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston. As the Director of Precision Oncology Program at the MGH Center for Breast Cancer, Dr. Bardia is interested in integrating precision diagnostics and therapeutics, including clinical application of circulating tumor cells and DNA as “liquid biopsy”, to significantly improve the outcomes of patients afflicted with breast cancer. Dr. Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, and selective estrogen receptor degrader (SERD), elacestrant, in metastatic breast cancer. Dr. Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO   molecular oncology tumor board.


M. Shaalan Beg, MD, MSM. Shaalan Beg, MD, MS
UT Southwestern Medical Center

Shaalan Beg MD MS, is an Associate Professor of Internal Medicine at UT Southwestern Medical Center. He is a Gastrointestinal Medical Oncologist at the Harold Simmons Comprehensive Cancer Center (SCCC), where he also serves as Medical Director of the Clinical Research Office. Dr. Beg completed his medical degree from the Aga Khan University in Karachi, Pakistan and his fellowship in Hematology/Medical Oncology at the University of Cincinnati. He proceeded to complete a Masters in Clinical Sciences from UT Southwestern Medical Center. He has expertise in early drug development and health services research with a focus on pancreatic cancer.

He is the Principal Investigator of the NCI Early Drug Development Opportunity Program (EDDOP) at SCCC and leads multiple investigator initiated clinical trials. Dr. Beg serves on the NCI Pancreatic Cancer Task Force of the GI Cancer Steering Committee and the ASCO Cancer Communications Committee.


Mariana Chavez Mac Gregor, MDMariana Chavez Mac Gregor, MD
The University of Texas MD Anderson Cancer Center

Mariana Chavez Mac Gregor, MD, is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. After finishing medical school at the Universidad Nacional Autónoma de México, she obtained a Master in Sciences degree in Clinical Epidemiology at the Netherlands Institute of Health and Sciences.  She completed her Clinical Residency in Internal Medicine at Barnes-Jewish Hospital/Washington University School of Medicine followed by a Clinical Fellowship in Medical Oncology at The University of Texas MD Anderson Cancer Center. She is an Associate Professor at The University of MD Anderson Cancer Center, holding a primary appointment in the Health Services Research Department, and a joint appointment in the Breast Medical Oncology Department.

In addition of being an active and compassionate clinician, Dr. Chavez MacGregor is committed to an academic a career, her research focuses on breast cancer outcomes and disparities research. She has extensive experience evaluating patterns of care, toxicities and complications of cancer treatment. In addition, she has been involved in the planning, design and implementation of clinical trials and is an active member of SWOG. She has received a number of awards including the SWOG Young investigator award and the Multinational Association of supportive Care in Cancer (MASCC) Young Investigator Award. She received the Achievement in Clinical Research Award and was recently honored with the MD Anderson Faculty Scholar Award. She holds leadership positions within ASCO, currently serving as the chair-elect of the Clinical Practice Guidelines Committee. Dr. Chavez Mac Gregor has written more than 100 articles, review articles, invited commentaries, and book chapters on breast cancer.


Alden Chiu MD, MPHAlden Chiu MD, MPH
Walter Reed National Military Medical Center

Alden Chiu, MD, MPH, is a Commander in the Medical Corps of the United States Navy.  He is stationed at Walter Reed National Military Medical Center (WRNMMC) where he serves as Assistant Chief for the Hematology-Oncology Service and as co-Chair of the Health Care Ethics Committee.  He is an Assistant Professor of Medicine at the Uniformed Services University of Health Sciences (USUHS) and specializes in hematologic and thoracic malignancies.  Dr. Chiu serves on the Peer Reviewed Cancer Programmatic Panel for the Congressional Directed Medical Research Program.

Dr. Chiu is a native of Seal Beach, California.  He received his medical degree from Weill Cornell Medical College and his masters from USUHS.  He completed internal medicine residency at Naval Medical Center San Diego and hematology/oncology fellowship at WRNMMC.  Past military assignments include service as a Battalion Surgeon with the 3rd Marine Logistics Group and as Assistant Director for Medical Operations on the hospital ship, USNS Mercy (T-AH 19).


Richard T. Lee, MDRichard T. Lee, MD
Case Western Reserve University & University Hospitals

Richard T. Lee, MD, is an Associate Professor in the Division of Hematology and Oncology and the Parker Hannifin-Helen Moss Cancer Research Foundation Professor of Integrative Oncology at Case Western Reserve University School of Medicine. Dr. Lee serves as Director of Supportive and Integrative Oncology at the University Hospitals Seidman Cancer Center (SCC), and as Director of the Case Center for Integrative Oncology. In these roles, he oversees the clinical, research and educational programs related to supportive and integrative oncology. As a medical oncologist, he provides routine oncologic care with a focus on hepatobiliary cancer.  Additionally, he provides broad consultative services regarding supportive and integrative cancer approaches.


Cornelia Liedtke, MD, PhDCornelia Liedtke, MD, PhD 
Charité-Universitätsmedizin Berlin

Cornelia Liedtke, MD, PhD, works as an Executive Senior Physician at the department of gynecology at the Charité Hospital Berlin, Germany. She trained at the Universities of Muenster and Luebeck, Germany, including a postdoc at the MD Anderson Cancer Center. She has received multiple national / international awards including SABCS scholarships and the ASCO merit award.

Prof. Liedtke’s research focuses on translational and clinical research in the field of breast cancer. She has published more than 100 peer-reviewed original articles, review articles and book chapters. She serves as associate editor for Breast Care and as a reviewer for numerous journals including the Journal of Clinical Oncology, the Lancet and Nature Reviews in Cancer. She is a member of the AGO Breast Committee responsible for breast cancer treatment guidelines in Germany.


Raymond Liu, MDRaymond Liu, MD
The Permanente Medical Group

Raymond Liu, MD, is the Chief of Hematology-Oncology at Kaiser Permanente San Francisco.  He completed his internal medicine and fellowship training at the University of California San Francisco (UCSF) and currently serves as Assistant Clinical Professor at UCSF for the Zuckerberg San Francisco General Hospital.  In addition, he serves as Regional Director of Cancer Survivorship and Co-Director of Regional Cancer Precision Tracking for the Permanente Medical Group, and is Secretary of the Association of Northern California Oncologists (ANCO). 

Dr. Liu is passionate about advancing systems-based improvements in cancer care, integrating technology into oncology practice, and improving cancer survivorship.  He recently initiated a new ACGME accredited hematology-oncology fellowship program at Kaiser Permanente San Francisco.


Shail Maingi, MDShail Maingi, MD
St. Peter's Health Partners Cancer Care

Shail Maingi, MD, is a community oncologist and hematologist at St. Peter’s Health Partners Cancer Care in Troy, NY.  Previously, she worked as an Assistant Professor at UMDNJ School of Medicine where her work focused on gastrointestinal malignancies, hematology, and cancer symptom management.  While there she was a principal investigator and co-investigator on several studies including studies on cancer outcomes in HIV-positive patients.  In her current practice, she is helping establish a clinical trial program and is the medical oncology lead on the Breast Program Leadership Committee.  Dr. Maingi earned her medical degree at Temple University School of Medicine. She completed her internship, residency, and hematology-oncology fellowship at Montefiore Medical Center in Bronx, NY.  Dr. Maingi also completed a pain and palliative care fellowship at Memorial Sloan Kettering Cancer Center. She has worked with several disenfranchised and underrepresented patient populations as both a clinician and an advocate.  Her advocacy work includes heading a research fund focused on the health disparities experienced by sexual minority women and serving on the Health Care Disparities Committee of the Medical Society of the State New York and the executive board of GLMA:  Health Professionals Advancing LGBTQ Equality. She has also worked on an ASCO subcommittee that was tasked with developing a policy on reducing cancer health disparities among sexual and gender minorities as well as a CDC-funded project defining best practices across the cancer continuum for this same patient population.  Dr. Maingi is also a board-certified palliative care physician  Working with ASCO and Health Volunteers Overseas, she partnered with a multidisciplinary, international team to help teach palliative care principles and pain management internationally.   She serves on the newly formed End-of-Life Committee of the Medical Society of the State of New York.  Dr. Maingi’s areas of research focus on dysfunction in hospice and palliative settings, and she is a national expert on the experiences of sexual and gender minorities in hospice and palliative settings.


Heather McArthur, MD, MPHHeather McArthur, MD, MPH
Cedars-Sinai Medical Center

Heather McArthur, MD, MPH, attended medical school at the University of Toronto, completed medical oncology training at the University of British Columbia, and earned a Masters degree in Public Health from Harvard University. She was awarded a Canadian grant which funded an advanced clinical breast cancer research fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. As faculty on the MSKCC Breast Medicine Service with an academic appointment at Cornell University Medical College between 2010-2016, she developed a research program focusing on immunotherapy strategies in breast cancer and mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies - two of which directly informed national (NCCN) treatment guidelines. She has served on the Conquer Cancer Foundation of American Society of Clinical Oncology (ASCO) YIA/CDA Grants Selection Committee, the ASCO Breast Cancer Symposium Program Committee, an ASCO Annual Meeting Scientific Program Committee, an ASCO Educational Book Expert Panel, the ASCO Grant Writing Workshop, a NCI-Breast Cancer Steering Committee Immuno-Oncology Working Group, a NCI Breast Cancer Immuno-Oncology Task Force, a Breast International Group (BIG) Immunotherapy Taskforce, and the Alliance for Clinical Trials in Oncology Immunotherapy/Immune Monitoring Working Group. She has conducted peer reviews for numerous journals including Science, the New England Journal of Medicine, and Cancer; and has written more than 70 articles, review articles, invited commentaries, and book chapters on breast cancer. She joined Cedars-Sinai Medical Center in 2016, as the Medical Director of Breast Oncology where she continues to investigate immune therapy and related strategies for the treatment of breast cancer.


Nathalie Dauphin McKenzie, MD, MSPHNathalie Dauphin McKenzie, MD, MSPH
Florida Hospital Cancer Institute

Nathalie Dauphin Mckenzie, MD, MSPH, serves as Director of Gynecologic Oncology Fellowship at Florida Hospital Cancer Institute. She earned her medical degree with research honors at the University of Buffalo, New York and undertook residency training and fellowship at the University of Miami/Jackson Memorial Hospital/ Sylvester Comprehensive Cancer Center. She also earned her Master of Science in Public Health and Epidemiology with honors while completing her fellowship training.  Dr. McKenzie who speaks four languages, is recipient of clinical excellence, exemplary physician awards as well as grant recipient of an ASCO Conquer Cancer YIA. She serves as reviewer for multiple journals, is a member of the SGO Wellness Task Force, and the FL, ASCO Clinical Practice Committee.  She has also served as principal investigator for numerous clinical trials, is a member of her institution’s clinical trial monitoring committee, has sat on the board of directors of non-profit organizations, and has gone on numerous medical missions and disaster relief to underdeveloped countries.


Sogol Mostoufi-Moab, MD, MSCESogol Mostoufi-Moab, MD, MSCE
The Children's Hospital of Philadelphia

Sogol Mostoufi-Moab, MD, MSCE, is an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine, with co-appointments in Endocrinology and Oncology at the Children’s Hospital of Philadelphia.  She received her Bachelor’s Degrees in French and Biology from University of Missouri-Columbia and her MD from Pennsylvania State University.  She completed a dual fellowship in Pediatric Endocrinology and Hematology/Oncology at the Children’s Hospital of Philadelphia and Master of Science in Clinical Epidemiology at the University of Pennsylvania. 

Dr. Mostoufi-Moab’s research focuses on addressing endocrine late effects and metabolic outcomes in childhood cancer survivors and includes epidemiologic and clinical trials.  Her research has been supported by grants from the NIH/NCI and St. Baldrick’s Foundation.  She treats patients with endocrine tumors and late effects after cancer therapy.  Dr. Mostoufi-Moab is a member of the Children’s Oncology Group and Childhood Cancer Survivor Study.  She has numerous peer-reviewed publications and serves on the Editorial Board for JCEM.


Ashley Love Sumrall, MD, FACP Ashley Love Sumrall, MD, FACP 
Levine Cancer Institute

Ashley Love Sumrall, MD, FACP, is a fellowship-trained neuro-oncologist who is board-certified in medical oncology and internal medicine. She is the Section Chief of neuro-oncology for Levine Cancer Institute in Charlotte, NC.  Her clinical interests include neuro-oncology, head and neck cancer, and neuroendocrine tumors. Dr. Sumrall received her MD from the University of Mississippi, then completed a residency in internal medicine at the University of Mississippi Medical Center. She completed her hematology/ oncology fellowship program at the University of Mississippi Medical Center. In 2011, she completed a neuro-oncology fellowship at the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center.

Dr. Sumrall has received the President’s award from Levine Cancer Institute and has been recognized for her commitment to patient care. She is President of the Board of Directors of a local nonprofit for patients who are chronically ill and homeless and is directing an initiative to provide housing for cancer patients who are homeless.


Mylin Torres, MDMylin Torres, MD
Winship Cancer Institute of Emory University

Mylin Torres, MD, is an Associate Professor in the Emory University School of Medicine Department of Radiation Oncology where she specializes in the treatment of breast cancer. She is currently Director of the multidisciplinary Emory Glenn Family Breast Center. Her research program is dedicated to understanding the biology underlying treatment-related side effects, including chronic inflammation and cancer-related fatigue.

As principal investigator, Dr. Torres has received grants from the National Cancer Institute, Radiation Therapy Oncology Group, Susan G. Komen, Avon Foundation, NCCN, Pfizer Oncology, and Winship Cancer Institute to support her research and efforts to improve disparities among African American patients.  She also serves on the editorial board of the Journal of Clinical Oncology. Dr. Torres holds the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Winship Cancer Institute.

Dr. Torres received Atlanta Business Chronicle’s Healthcare Heroes Rising Star and Winship Cancer Institute’s Above and Beyond Awards.  Atlanta Magazine also named her as one of the “Women Making a Mark” in the Atlanta community.  Dr. Torres graduated magna cum laude from Harvard University and received her medical degree from Stanford University before completing her training in radiation oncology at The University of Texas MD Anderson Cancer Center.


Andrew Z. Wang, MDAndrew Z. Wang, MD
University of North Carolina at Chapel Hill

Andrew Z. Wang, MD, is Associate Professor and Director of Clinical and Translational Research, Department of Radiation Oncology, UNC-Chapel Hill. He is also the co-Director of the Carolina Cancer Nanotechnology T32 training program. Dr. Wang earned his undergraduate degrees from Indiana University and medical degree from the HST program at Harvard Medical School. He completed his radiation oncology training in the Harvard Radiation Oncology Program. Following residency, Dr. Wang joined the UNC faculty in 2009.

Dr. Wang’s research program is focused on the clinical translation of engineering sciences, including Nanomedicine, to oncology. His research spans a wide spectrum of translational research, from preclinical research to early phase clinical trials. His research has been supported by grants from the NIH/NCI and Department of Defense. He is CEO and cofounder of Capio Biosciences, a biotech startup that is translating a nanotechnology-based circulating tumor cell capture assay. Dr. Wang is on the editorial board of several journals, including Journal of the National Cancer Institute.erve as the 2014-5 University of Iowa Faculty Senate President and received the University of Iowa Brody Award for Faculty Excellence in Service.